Cemiplimab before and after surgery for high-risk skin cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This Phase 1 trial tests the drug cemiplimab given before and after surgery to reduce the chance that high-risk cutaneous squamous cell cancer comes back. You may be a candidate if your cancer is high-risk on pathology or imaging and is planned for surgical removal.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have high-risk cutaneous squamous cell cancer (for example: spread to lymph nodes with tumor growth outside the node, certain large/in-transit skin metastases, nerve involvement, or a recurrent tumor with other high-risk features).
- Your cancer must be judged surgically removable (your surgical team plans the surgery before the study treatment).
- You have not had prior systemic immunotherapy or any prior anti–PD-1 treatment (like drugs in the same class as cemiplimab).
- You must be able to do study procedures and visits (and be well enough for treatment), with good basic blood counts and liver/kidney tests.
- You must not be pregnant or breastfeeding, and you must agree to effective birth control during the study and for at least 6 months after stopping the drug.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug (cemiplimab) injected directly into early-stage skin cancer (squamous cell carcinoma) to see if it can shrink or cure the cancer before surgery. It may help patients avoid more extensive surgery or reduce the chance of the cancer coming back.
This early-phase study tests cemiplimab (an immune therapy that helps your immune system attack cancer) given before surgery. It aims to shrink tumors and improve outcomes for people with Merkel cell cancer or certain locally advanced skin squamous cell cancers (CSCC).
This trial tests whether the immunotherapy drug cemiplimab can treat advanced squamous cell skin cancer in people who have had a kidney transplant. It aims to see if the drug can shrink tumors while keeping the transplanted kidney working well.
This trial tests combining a skin cream (imiquimod), a laser treatment, and an immunotherapy drug (cemiplimab) before surgery for high-risk basal cell carcinoma. The goal is to see if this combination shrinks tumors enough to make surgery less disfiguring or damaging to nearby functions.
This trial tests if the immunotherapy drug cemiplimab, given before and after surgery, can help treat early-stage non-small cell lung cancer that has high levels of a protein called PD-L1. If you have stage II or IIIA lung cancer that can be surgically removed and your tumor has PD-L1 expression of 50% or more, you may be eligible.
This trial tests cemiplimab, an immunotherapy drug, as a first treatment for advanced basal cell carcinoma that cannot be removed with surgery or radiation. The goal is to see if it can shrink or control the cancer.
Hear when a new Metastatic Skin Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.